Earnings History Data for Ovid Therapeutics (OVID) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Ovid Therapeutics
Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12-11-2024 | PM | OVID | Ovid Therapeutics | 92.00 | -0.20 | -0.19 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $0.17M beats by $0.1M [11/12/2024 8:51 AM] |
1.28 | -0.08 (-5.95%) |
1.38 | 0.02 (1.47%) |
0.68 - 4.10 | 148,797 | 250,000 | 559 | ||
| 13-08-2024 | PM | OVID | Ovid Therapeutics | 64.00 | 0.12 | -0.22 | 0.00 | Ovid Therapeutics GAAP EPS of $0.12, revenue of $0.17M [8/13/2024 8:57 AM] |
0.87 | 0.03 (2.97%) |
0.0 | 0.0 (0.00%) |
0.68 - 4.14 | 165,658 | 200,000 | 0 | ||
| 14-05-2024 | PM | OVID | Ovid Therapeutics | 212.00 | -0.17 | -0.23 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.17 [5/14/2024 10:32 AM] |
3.23 | 0.21 (6.95%) |
0.0 | 0.0 (0.00%) |
2.57 - 4.14 | 104,861 | 110,000 | 0 | ||
| 08-03-2024 | PM | OVID | Ovid Therapeutics | 230.00 | -0.22 | -0.17 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.22 misses by $0.19, revenue of $0.14M [3/8/2024 8:24 AM] |
3.09 | -0.08 (-2.52%) |
0.0 | 0.0 (0.00%) |
1.90 - 4.14 | 70,465 | 150,000 | 0 | ||
| 03-11-2023 | PM | OVID | Ovid Therapeutics | 253.00 | -0.16 | -0.18 | 0.00 | Ovid Therapeutics reports Q3 results [11/3/2023 10:19 AM] |
3.58 | 0.05 (1.42%) |
3.51 | -0.02 (-0.57%) |
1.40 - 4.14 | 91,629 | 110,000 | 306 | ||
| 04-08-2023 | PM | OVID | Ovid Therapeutics | 233.00 | -0.18 | -0.21 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.18 beats by $0.03 [8/4/2023 12:26 PM] |
3.49 | 0.17 (5.12%) |
3.50 | 0.18 (5.42%) |
1.40 - 3.98 | 102,869 | 150,000 | 360 | ||
| 05-05-2023 | PM | OVID | Ovid Therapeutics | 255.00 | -0.19 | -0.18 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.19 misses by $0.02, revenue of $0.07M beats by $0.05M [5/5/2023 7:56 AM] |
3.64 | -0.01 (-0.27%) |
0.0 | 0.0 (0.00%) |
1.40 - 3.70 | 122,838 | 130,000 | 0 | ||
| 13-03-2023 | PM | OVID | Ovid Therapeutics | 152.00 | -0.16 | -0.19 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.16 beats by $0.02 [3/13/2023 8:20 AM] |
2.01 | 0.01 (0.50%) |
2.00 | 0.0 (0.00%) |
1.40 - 3.40 | 29,571 | 90,000 | 480 | ||
| 08-11-2022 | PM | OVID | Ovid Therapeutics | 107.00 | -0.17 | -0.21 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.17 beats by $0.04 [11/8/2022 8:57 AM] |
1.48 | 0.04 (2.78%) |
0.0 | 0.0 (0.00%) |
1.40 - 3.70 | 89,594 | 70,000 | 0 | ||
| 09-08-2022 | PM | OVID | Ovid Therapeutics | 155.00 | -0.21 | -0.23 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04 [8/9/2022 8:29 AM] |
2.22 | 0.02 (0.91%) |
0.0 | 0.0 (0.00%) |
1.65 - 4.20 | 30,587 | 90,000 | 0 | ||
| 10-05-2022 | PM | OVID | Ovid Therapeutics | 199.00 | -0.23 | 1.17 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.23 misses by $0.02, revenue of $1.45M [5/10/2022 8:46 AM] |
2.84 | 0.02 (0.71%) |
2.77 | -0.05 (-1.77%) |
2.60 - 4.80 | 38,077 | 154,971 | 1,247 | ||
| 15-03-2022 | PM | OVID | Ovid Therapeutics | 230.00 | -0.38 | -0.17 | 0.00 | Ovid Therapeutics GAAP EPS of -$0.38 misses by $0.22 [3/15/2022 9:02 AM] |
3.14 | -0.06 (-2.03%) |
3.15 | -0.05 (-1.56%) |
0.0 - 0.0 | 64,739 | 0 | 0 | ||
| 10-11-2021 | PM | OVID | Ovid Therapeutics | 245.00 | -0.17 | -0.19 | 0.00 | Ovid Therapeutics EPS beats by $0.03 [11/10/2021 8:43 AM] |
3.51 | -0.10 (-2.77%) |
0.0 | 0.0 (0.00%) |
2.25 - 6.98 | 204,667 | 170,000 | 0 | ||
| 13-05-2021 | AH | After the close (May 13) |
OVID | Ovid Therapeutics Inc. | 235.23 | 2.53 | 1.31 | -0.37 | Ovid Therapeutics EPS beats by $1.80, beats on revenue [5/13/2021 5:08 PM] |
3.60 | 0.30 (9.09%) |
3.51 | 0.21 (6.36%) |
2.25 - 9.40 | 1,067,513 | 650,000 | 19,048 | |
|
||||||||||||||||||
| 15-03-2021 | PM | OVID | Ovid Therapeutics Inc. | 260.08 | -0.34 | -0.31 | -0.35 | Ovid Therapeutics EPS misses by $0.04, beats on revenue [3/15/2021 9:29 AM] |
0.0 | 0.0 (0.00%) |
0.0 | 0.0 (0.00%) |
0.0 - 0.0 | 0 | 0 | 0 | ||
| 15-03-2021 | PM | OVID | Ovid Therapeutc | 266.00 | -0.34 | -0.31 | 0.00 | Ovid Therapeutics EPS misses by $0.04, beats on revenue [3/15/2021 9:29 AM] |
4.11 | 0.01 (0.24%) |
4.05 | -0.05 (-1.12%) |
1.80 - 9.40 | 1,259,138 | 15,646,321 | 31,124 | ||
| 12-11-2020 | AH | OVID | Ovid Therapeutics Inc. | 326.17 | -0.28 | -0.43 | -0.43 | Ovid Therapeutics EPS beats by $0.14, beats on revenue [11/12/2020 4:50 PM] |
6.05 | 0.63 (11.62%) |
5.50 | 0.08 (1.48%) |
1.80 - 9.40 | 1,564,393 | 624,529 | 3,809 | ||
|
|
||||||||||||||||||